The 10-second takeaway
For the quarter ended March 31 (Q1), Cynosure beat expectations on revenues and missed estimates on earnings per share.
Compared to the prior-year quarter, revenue grew significantly. GAAP earnings per share expanded.
Margins increased across the board.
Cynosure recorded revenue of $40.7 million. The three analysts polled by S&P Capital IQ foresaw a top line of $38.8 million on the same basis. GAAP reported sales were 19% higher than the prior-year quarter's $34.2 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.07. The four earnings estimates compiled by S&P Capital IQ predicted $0.13 per share. GAAP EPS of $0.07 for Q1 were 17% higher than the prior-year quarter's $0.06 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 58.2%, 110 basis points better than the prior-year quarter. Operating margin was 4.9%, 240 basis points better than the prior-year quarter. Net margin was 3.0%, 60 basis points better than the prior-year quarter. (Margins calculated in GAAP terms.)
Next quarter's average estimate for revenue is $45.2 million. On the bottom line, the average EPS estimate is $0.18.
Next year's average estimate for revenue is $181.0 million. The average EPS estimate is $0.73.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 371 members out of 386 rating the stock outperform, and 15 members rating it underperform. Among 84 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 77 give Cynosure a green thumbs-up, and seven give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Cynosure is buy, with an average price target of $35.60.
Is Cynosure the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Cynosure to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.